Magenta Therapeutics enters amended employment agreements with two executives

Dianthus Therapeutics, Inc. /DE/

Thomas Beetham (CLO) base salary $435,000, target incentive 40% of base, amended severance details.
David Nichols (CTO) base salary $362,000, target incentive 40% of base, amended severance details.
Severance: 0.75x base plus pro-rata target outside change in control; 1x base plus 100% target and accelerated vesting within change in control period.
Agreements effective May 2, 2022, supersede prior employment agreements.
Standard COBRA subsidies included; subject to release and noncompetition covenant.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.